Multiple endocrine neoplasia type 1 (MEN1)

Print this article

Multiple endocrine neoplasia type 1, usually shortened to MEN1, is an inherited condition that causes tumors to develop in several hormone-producing glands. It is caused by a change in a single gene, also called MEN1, which makes a protein named menin. It affects roughly 1 in 20,000 to 1 in 40,000 people.

Three glands are most often involved, sometimes called the three Ps: the parathyroid glands in the neck, the pancreas and the neighboring duodenum, and the pituitary gland at the base of the brain. Tumors can also arise in the thymus, lungs, stomach, and adrenal glands, and several harmless skin growths are part of the condition.

MEN1 differs from most conditions in this section in an important way. Most of the tumors it causes are not cancer. They are benign growths that cause problems by producing too much of a hormone rather than by spreading. The exception matters: neuroendocrine tumors of the pancreas, duodenum, and thymus can behave as cancers, and they are the main reason this condition shortens life. Care therefore targets two problems at once: controlling hormone effects and watching for tumors that can spread.

This article is written for people who carry a change in the MEN1 gene, whether or not they have developed any tumors.

What does the MEN1 gene do?

The MEN1 gene carries the instructions for a protein called menin, which works inside the nucleus of cells and helps control when genes are switched on and off. Through that role, it restrains the growth and division of cells in hormone-producing tissues.

MEN1 is a tumor suppressor gene, and everyone carries two copies. A person with MEN1 is born with one working copy and one that does not work. That single copy is enough for normal function, but if it is lost in any individual cell of an at-risk gland, that cell begins to multiply without restraint and forms a tumor.

This mechanism explains a pattern that is otherwise puzzling. Tumors in MEN1 are usually multiple rather than solitary, and they keep appearing over a lifetime. Every cell in every parathyroid gland, and every hormone-producing cell in the pancreas, is one step from losing the brake. Removing one tumor does not remove the underlying tendency, which is why surgery is planned with the knowledge that more tumors are likely to follow, and why operations aim to preserve as much gland function as possible.

Tumors associated with MEN1

Overactive parathyroid glands

The parathyroid glands sit behind the thyroid in the neck and control blood calcium levels. Overactivity of these glands is the most common feature of MEN1 and usually the first to appear, affecting roughly 95% of carriers. It generally begins in the twenties or thirties, decades earlier than in the general population, and has been found in children as young as eight.

In MEN1, the abnormality typically affects all four glands rather than one, which is the main difference from ordinary parathyroid disease. Your report may describe an enlarged hypercellular gland or a parathyroid adenoma. Raised calcium causes tiredness, low mood, kidney stones, and bone thinning, and it is often found on a blood test before symptoms appear. Parathyroid carcinoma is rare in MEN1.

Neuroendocrine tumors of the pancreas and duodenum

These are the most serious tumors in MEN1, developing in roughly 40% to 75% of carriers, depending on how closely they are monitored. They arise from neuroendocrine cells, which sit between the nervous and hormonal systems. Most are well-differentiated neuroendocrine tumors that arise in the pancreas or duodenum (the first part of the small intestine), and, as in the parathyroid glands, they are usually multiple.

Some produce hormones, and some do not, and this distinction shapes how they are found and managed:

Gastrinomas — Produce gastrin, which drives the stomach to make excess acid, causing stubborn ulcers and diarrhea. In MEN1, these usually arise in the wall of the duodenum rather than the pancreas, and they are often small and multiple. This picture was historically called Zollinger-Ellison syndrome.
Insulinomas — Produce insulin, causing episodes of low blood sugar with confusion, sweating, and shakiness, often before meals or overnight. These are usually small and are almost always benign.
Non-functioning tumors — Produce no hormone that causes symptoms. These are the most common in MEN1 and are found through scanning rather than symptoms. Because they are silent, they can grow before they are noticed, and they carry the highest risk of spreading.

Together with tumors of the thymus, these are the leading cause of death related to MEN1, which is why imaging of the abdomen forms the core of surveillance.

Pituitary tumors

The pituitary gland sits at the base of the brain and directs several other hormone systems. Pituitary adenomas occur in roughly 30% to 40% of people with MEN1. Nearly all are benign, and they cause problems in two ways: by producing too much hormone, or by growing large enough to press on surrounding structures, including the nerves that carry vision.

The most common type produces prolactin, which can cause irregular or absent periods and infertility in women and reduced sex drive and fertility in men, sometimes with milk production in either. Tumors producing growth hormone cause gradual enlargement of the hands, feet, and facial features. Many prolactin-producing tumors are treated effectively with medication rather than surgery.

Other tumors

Thymus and lung neuroendocrine tumors — Uncommon, occurring in roughly 3% to 10%, but tumors of the thymus behave more like cancer than most tumors in this syndrome and occur mainly in men who smoke.
Stomach neuroendocrine tumors — Well differentiated neuroendocrine tumors of the stomach can develop, usually as a consequence of the high acid levels driven by a gastrinoma.
Adrenal tumors — Adrenal cortical adenomas are found in a substantial minority. Most are harmless and produce no hormone.
Skin growths — Small facial bumps called angiofibromas, firm patches called collagenomas, and lipomas, which are soft fatty lumps. None of these is dangerous, but they are common enough that a dermatologist may be the first to suspect the diagnosis.
Breast cancer — Women with MEN1 appear to have a modestly increased risk, and some centers offer earlier breast screening.

How lifetime risk is estimated and why the numbers vary

MEN1 is unusual in this section because the overall penetrance is genuinely very high. Around 95% of carriers develop at least one feature by age 40, and close to all do by age 80. Most people who carry a change in this gene will develop something, and the figures here have held up better than in most hereditary syndromes as testing has widened.

What varies is which tumors, when, and how severe. Three points explain the ranges quoted above:

How hard anyone looked — The figure for pancreatic neuroendocrine tumors ranges from roughly 40% to 75%, and much of that gap reflects surveillance intensity rather than biology. Sensitive imaging finds small tumors that would otherwise never have been counted.
No useful link exists between the specific change and the outcome — Unlike MEN2, where the exact position in the gene sets the management plan, MEN1 has no reliable genotype-phenotype correlation. Two people with the same change, even within one family, can have quite different courses. This is why surveillance covers all the at-risk glands in everyone rather than being tailored to the variant.
The figures describe features, not deaths — A 95% chance of developing overactive parathyroid glands is not a 95% chance of a life-threatening problem. Most MEN1 tumors are benign and manageable. The serious risk is concentrated in the pancreatic, duodenal, and thymic neuroendocrine tumors.

The practical consequence is that a carrier should expect to develop something, probably beginning with the parathyroid glands in early adulthood, and that most of what develops will be treatable. Surveillance exists to find the small proportion that is dangerous while it is still curable.

Who should be tested?

Genetic testing for MEN1 is generally offered when:

Two or more of the three main tumor types are present in the same person, which is the clinical definition of the syndrome.
One of the main tumors is present alongside a first-degree relative with MEN1.
Overactive parathyroid glands occur at a young age, generally under 40, or involve more than one gland, or return after surgery.
A gastrinoma or a pancreatic neuroendocrine tumor is diagnosed at any age, particularly when multiple.
A pituitary adenoma occurs at a young age, generally under 30, or in a child.
A known gene change has already been identified in the family.

Roughly 10% of people with MEN1 have a new gene change rather than an inherited one, so an absent family history does not exclude the diagnosis.

How the test is performed

Germline testing is done on a blood or saliva sample and examines the DNA a person was born with. The laboratory sequences the MEN1 gene using next generation sequencing, together with a method that detects large deletions, since a proportion of changes in this gene are missing sections rather than single-letter changes.

When the clinical picture fits MEN1 but no MEN1 change is found, doctors sometimes test a related gene called CDKN1B. Changes in it cause a similar but rarer condition, and it accounts for a small number of families.

Blood tests are used alongside the genetic result, not instead of it. Calcium and parathyroid hormone track the parathyroid glands, prolactin and a growth hormone marker track the pituitary, and gut hormone levels track the pancreas and duodenum.

How results are reported

Pathogenic or likely pathogenic variant — A change known, or strongly expected, to stop the gene working. This confirms MEN1.
Variant of uncertain significance — A change was found, but its effect is unknown. This is not a positive result. It is managed as though negative, with monitoring guided by the clinical picture and family history, and it is never a basis for preventive surgery. Our article on variants of uncertain significance explains this result in detail.
Benign or likely benign variant — A harmless difference, usually not reported.
No variant identified — No change was found in the genes tested.

What the result means

A pathogenic or likely pathogenic variant confirms MEN1 and starts lifelong surveillance of the at-risk glands. Each child, sibling, and parent has a 50% chance of carrying the same change. Because the specific change does not predict which tumors will develop, the result establishes that surveillance is needed rather than what to expect.

A negative result means two different things:

True negative — A specific change is already known in your family and you tested negative for that exact change. You did not inherit it, you do not need surveillance, and your children cannot inherit it from you. In a family with MEN1 this result releases a person from decades of annual blood tests and scans.
Uninformative negative — No change has been identified in anyone in the family. Someone who meets the clinical definition of MEN1 but has no identifiable gene change tends to follow a milder course, and current guidance is that their relatives do not need the same surveillance as relatives of a gene-positive family. Their own monitoring continues based on the tumors they have.

Germline versus somatic MEN1 changes

A germline change is present in the DNA a person was born with, exists in every cell, and can be passed to children. That is the syndrome.

A somatic change arises within a tumor during life, exists only in the tumor cells, and cannot be inherited.

Somatic MEN1 changes are common in tumors that have nothing to do with the syndrome. They are found in a substantial proportion of ordinary pancreatic neuroendocrine tumors and parathyroid adenomas occurring in people who do not carry an inherited change. A tumor sequencing report naming MEN1 is therefore an expected finding and does not establish the syndrome. MEN1 is suggested by the pattern: more than one gland involved, tumors appearing young, multiple tumors within one gland, or a family history. Confirming it requires a separate germline test on blood or saliva.

Surveillance and management

Surveillance in MEN1 is lifelong and combines blood tests with imaging. It generally begins in childhood, since the parathyroid glands can become overactive by age eight and pituitary tumors have been found in children. Most centers start blood testing around age five to ten and add imaging in the teenage years.

What surveillance involves

Annual blood tests — Calcium and parathyroid hormone for the parathyroid glands, prolactin and a growth hormone marker for the pituitary, and gut hormone levels for the pancreas and duodenum.
Abdominal imaging — MRI, CT, or endoscopic ultrasound of the pancreas and duodenum every one to three years, beginning in adolescence. MRI is often preferred to limit lifetime radiation exposure.
Pituitary MRI — Every one to three years, or sooner if blood tests or symptoms suggest a problem.
Chest imaging — Every one to two years to look for thymic and lung tumors, particularly in men who smoke.

This is a substantial amount of medical contact sustained over decades, and it has costs of its own. Repeated scans find small abnormalities that require follow-up and often turn out to be harmless, and the accumulated worry is real. Centers that manage MEN1 regularly are generally better placed to judge which findings need action and which can be watched.

Treating the parathyroid glands

Surgery treats overactive parathyroid glands, and it is approached differently here than in ordinary parathyroid disease. Because all four glands are usually abnormal, removing only the largest one leads to recurrence. Surgeons therefore remove most of the parathyroid tissue, leaving a small amount behind or transplanting a fragment into the forearm, where it is easier to reach if further surgery is needed.

The balance is between leaving too much tissue, which means the problem returns, and leaving too little, which means permanently low calcium requiring calcium and vitamin D for life. Neither outcome is rare, and the timing and extent of surgery are decided on an individual basis.

Managing pancreatic and duodenal tumors

This is the most difficult area of MEN1 care, because these tumors are usually multiple and continue to appear, so removing every one is neither possible nor desirable. Repeated pancreatic surgery carries real consequences, including diabetes and problems digesting food.

The general approach is to treat tumors that cause hormone problems and to watch small non-functioning tumors, with surgery considered when a tumor grows beyond a certain size or grows quickly. Acid-blocking medication controls the effects of a gastrinoma effectively, and surgery for gastrinoma in MEN1 is approached cautiously because the tumors are small, multiple, and often in the duodenal wall. Where tumors have spread, treatments used for neuroendocrine tumors generally apply, including hormone-blocking injections, targeted drugs, and radioactive treatments directed at the tumor.

Treating pituitary tumors

Prolactin-producing tumors usually respond well to tablets that shrink them, and surgery is often unnecessary. Other types are treated with surgery through the nose, sometimes followed by medication or radiotherapy.

Testing family members

MEN1 is inherited in an autosomal dominant pattern, meaning a single altered copy causes it. Each child, sibling, and parent of a carrier has a 50% chance of carrying the same change, and it passes through fathers as well as mothers.

Once a specific change is identified, relatives are tested for that exact change through cascade testing.

Children are tested in childhood rather than at adulthood. The reason is that surveillance begins young: overactive parathyroid glands have been documented from age eight and pituitary tumors in children, so a child who carries the change needs blood tests from around age five to ten. A child who tests negative avoids all of it. Testing is usually offered in the preschool or early school years, and genetics services and pediatric endocrinologists support families through the decision.

Where the change arose new in a person, their parents and siblings are usually unaffected, though testing may still be offered.

Carriers planning a family sometimes ask whether they can avoid the change in their children. Preimplantation genetic testing, in which embryos created through IVF are tested before transfer, and prenatal testing are available in many places. A genetics service and a fertility specialist can work through these options together.

What happens next

For someone newly diagnosed, the first step is a full assessment of all at-risk glands, since more than one is often already involved when the diagnosis is made. A surveillance schedule follows, along with referral for family testing.

For a carrier identified through family testing, the work is establishing that surveillance schedule and keeping to it over decades.

An endocrinologist usually coordinates care, working with endocrine surgery, gastroenterology, radiology, and genetics. Referral to a center that manages MEN1 regularly matters here more than in most conditions, because decisions about when to operate on a pancreas full of small tumors depend heavily on experience.

Living with MEN1 means an ongoing relationship with the health system rather than a single episode of treatment, often beginning in childhood and continuing for life, with the knowledge that new tumors are likely to appear. Experienced centers include psychological support as part of care, and MEN1 patient organizations connect families managing the same long horizon.

Questions to ask your doctor

Which of my glands are currently affected, and which are being watched?
What are my calcium and parathyroid hormone levels, and do they suggest my parathyroid glands are overactive?
Have any tumors been found in my pancreas or duodenum, and are any of them producing hormones?
If a pancreatic tumor was found, how large is it, and are we watching it or treating it?
Has my pituitary gland been imaged, and were my prolactin and growth hormone levels normal?
What surveillance schedule do you suggest, and which tests will I have each year?
Will imaging use MRI rather than CT, given how many scans I will have over a lifetime?
If I need parathyroid surgery, how much tissue would be left behind, and what happens if my calcium becomes too low?
Should I be seen at a center that specializes in this condition?
Which of my relatives should be tested, and at what age should my children be tested?
What surveillance would my children need, and when would it start?
Do I need earlier breast screening?
What reproductive options are available if I want to avoid passing this on?
Is psychological support or a patient organization available to my family?